Key result
Natriuretic peptides (BNP and NT-proBNP) provide independent and incremental prognostic value for mortality in patients with acute coronary syndromes.
Why the study?
Do natriuretic peptides (BNP and NT-proBNP) provide prognostic value for mortality in patients with acute coronary syndromes?
Meta-Analysis
Do natriuretic peptides (BNP and NT-proBNP) provide prognostic value for mortality in patients with acute coronary syndromes?
BNP and NT-proBNP measurement provides independent prognostic value for mortality in ACS patients and should be integrated into routine evaluation.
Answers are grounded in this paper and cite their sources.
May refine ACS mortality risk stratification beyond troponin; leaves open impact on therapy decisions.
Natriuretic peptides (BNP and NT-proBNP) have been shown to be useful tools for risk stratification of patients with acute myocardial ischemia encompassing the whole spectrum of acute coronary syndromes (ACS), particularly for prediction of mortality. Both BNP and NT-proBNP possess several characteristics of the ideal biomarker, showing independent and incremental prognostic value above traditional clinical, electrocardiographic, and biochemical (particularly troponin) risk indicators. Specifically, in ACS patients, BNP and NT-proBNP have powerful prognostic value both in patients without a history of previous heart failure or without clinical or instrumental signs of left ventricular dysfunction on admission or during hospital stay. They can also be easily and rapidly measured in an emergency context. We have performed a meta-analysis of available studies concerning the prognostic value of natriuretic peptides. Our results show that the prognostic value of natriuretic peptides is similar: (1) both at short- and long-term; (2) when natriuretic peptides are measured at first patient contact or during hospital stay; (3) for BNP or NT-proBNP; and (4) in patients with ST elevation myocardial infarction or no ST elevation ACS. These data suggest that natriuretic peptide measurement should be integrated into routine evaluation of patients with an ACS.
No takes yet. Share an insight, caveat, or question.
Galvani et al. (2004) conducted a meta-analysis in Acute coronary syndromes (ACS). Natriuretic peptides (BNP and NT-proBNP) was evaluated on Prognostic value for mortality. Natriuretic peptides (BNP and NT-proBNP) provide independent and incremental prognostic value for mortality in patients with acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: